|
|
|
|
|
|
Sponsored by: |
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00075595 |
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one chemotherapy drug may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving fluorouracil together with leucovorin and irinotecan works in treating patients with recurrent or refractory metastatic unresectable colorectal cancer.
Condition | Intervention | Phase |
Colorectal Cancer |
Drug: fluorouracil Drug: irinotecan hydrochloride Drug: leucovorin calcium |
Phase II |
MedlinePlus related topics: | Cancer Colorectal Cancer |
ChemIDplus related topics: | Leucovorin Calcium Citrovorum factor Folinic acid calcium salt pentahydrate Leucovorin Irinotecan Irinotecan hydrochloride Fluorouracil Calcium gluconate |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase II Study of 5FU/Folinic Acid and Irinotecan as Second or Third Line Treatment in Patients With Metastatic, Unresectable, Colorectal Cancer |
Study Start Date: | June 2002 |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is an open-label, multicenter study.
Patients receive leucovorin calcium IV over 2 hours on day 1, irinotecan IV over 1 hour on days 1 and 3, and fluorouracil IV continuously over 46 hours beginning on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 78 patients will be accrued for this study within 18 months.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed colorectal adenocarcinoma
Meets 1 of the following criteria:
Progressive disease as defined by 1 of the following criteria:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Gastrointestinal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
France | |||||
American Hospital of Paris | |||||
Neuilly Sur Seine, France, F-92202 | |||||
Centre Hospital Universitaire Hop Huriez | |||||
Lille, France, 59037 | |||||
Centre Medico-Chirurgical Foch | |||||
Suresnes, France, 92151 | |||||
Clinique Armoricaine De Radiologie | |||||
Saint Brieuc, France, F-22015 | |||||
Clinique de l'Orangerie | |||||
Strasbourg, France, 67010 | |||||
Clinique Saint Jean | |||||
Lyon, France, 69008 | |||||
Clinique Ste - Marie | |||||
Pontoise, France, 95300 | |||||
Polyclinique De Courlancy | |||||
Reims, France, F-51100 | |||||
Hopital Drevon | |||||
Dijon, France, 21000 | |||||
Hopital Europeen Georges Pompidou | |||||
Paris, France, 75015 | |||||
Hopital Saint Antoine | |||||
Paris, France, 75571 | |||||
Hopital Saint Joseph | |||||
Marseille, France, 13008 | |||||
Hopital Tenon | |||||
Paris, France, 75970 | |||||
Intercommunal Hospital | |||||
Montfermeil, France, 93370 | |||||
Hopital Bichat - Claude Bernard | |||||
Paris, France, 75018 |
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) |
Investigator: | May Mabro, MD | Hopital Foch |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000347378, FRE-GERCOR-FOLFIRI3-C00-2, EU-20333 |
First Received: | January 9, 2004 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00075595 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|